If you or a loved one were diagnosed with gastroparesis (stomach paralysis), ileus, or intraoperative pulmonary aspiration or suffered other issues (such as sudden vision loss) after taking Ozempic, Mounjaro, Wegovy or Rybelsus, you may be entitled to recover compensation from an Ozempic lawsuit case or settlement claim.
A team of drug injury lawyers and class action attorneys is investigating potential Ozempic lawsuit and settlement cases of individuals who suffered from stomach paralysis (gastroparesis), ileus (lack of movement through intestines), intraoperative pulmonary aspiration or other gastrointestinal problems after using Ozempic or other GLP-1 agonists.
Ozempic (semaglutide) is a prescription drug in a class of medications called GLP-1 agonists (a/k/a glucagon-like peptide-1 receptor agonists, GLP-1 receptor agonists GLP-1-RA, incretin mimetics, or GLP-1 analogs) that have been used to treat type 2 diabetes and obesity by lowering blood sugar, helping the pancreas produce more insulin, and slowing the rate that food passes through the body. They work by binding to and activating GLP-1 receptors in cells to trigger the production of insulin (a hormone which converts glucose into energy) and suppressing the release of glucagon (a hormone that raises blood sugar). Other GLP-1 agonists include Mounjaro, Wegovy, and Rybelsus.
In recent years, billions of dollars have been spent on (and tens of millions of prescriptions have been written for) Ozempic and other GLP-1 agonists. Unfortunately, patients who took Ozempic or other diabetes and/or weight loss drugs may potentially be at an increased risk of developing severe gastrointestinal side effects, such as gastroparesis (stomach paralysis), ileus (intestinal obstruction or decrease or stoppage of flow of intestinal contents), intraoperative pulmonary aspiration (entry of liquid or solid material in trachea or lungs) and other GI injuries.
Ozempic Lawsuit & Settlement Cases
Ozempic lawsuit and settlement cases potentially being investigated include claims involving individuals who suffered from gastroparesis or other stomach problems after taking Ozempic and/or other medications to treat diabetes and/or obesity, including:
- Ozempic (semaglutide)
- Wegovy (semaglutide)
- Rybelsus (semaglutide)
- Mounjaro (tirzepatide)
- Other GLP-1 agonist medications
- Other diabetes or weight loss drug lawsuit cases
Ozempic lawsuits filed in federal court have been transferred into a multi-district litigation (MDL) for consolidation and coordination of pretrial proceedings to the Eastern District of Pennsylvania in IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL Case No. 3094.
Plaintiffs in the Ozempic lawsuits allege, among other things, that they suffered gastrointestinal and associated injuries after receiving GLP-1 receptor agonists, such as Ozempic, Wegovy, Rybelsus and Mounjaro and that defendants knew or should have known that GLP-1 RA drugs can cause gastroparesis and other GI injuries but failed to provide an adequate warning. The Ozempic lawsuit complaints assert claims for, among other things, negligence, strict liability, breach of warranty, negligent/fraudulent misrepresentation, and violation of state statutes.
Defendants in the Ozempic lawsuits have included manufacturers, sellers and/or distributors of GLP-1 receptor agonists, such as Novo Nordisk (Ozempic, Rybelsus and Wegovy) and Eli Lilly (Mounjaro).
Ozempic Lawsuit & Settlement Updates
Recent updates about Ozempic lawsuits and settlements include:
- May 2024: On May 17, 2024, attorneys for plaintiffs filed a status report informing the Court on the status of the parties’ discussions regarding the terms of a proposed Plaintiff Fact Sheet (“PFS”), selection of vendors to handle PFS information, authorizations for release of medical records and collection of medical records, and various discovery related orders, among other things.
- April 2024: On April 9, 2024, the parties filed joint suggestions for an April 18 conference with the Court that was held, including an update on case inventory, science day, motion practice, fact sheets, electronic service, discovery and scheduling additional status conferences.
- March 2024: On March 14, 2024, the Court held an initial case management conference to discuss, among other things, various organizational and procedural issues, such as leadership structure for the plaintiffs, plaintiff fact sheets about the different GLP-1 receptor drugs that may have been taken and the alleged injuries that plaintiffs claim to have suffered as a result of taking the medications.
Older Ozempic lawsuit and settlement updates
- September 2023: On September 22, 2023, the FDA approved a drug label change indicating that Ozempic has the potential to lead to gastrointestinal disorders including Ileus (a non-mechanical bowel obstruction).
- March 2022: In March of 2022, the FDA approved a drug label change indicating that acute events of gallbladder disease such as cholelithiasis (gallstones) or cholecystitis (inflammation of the gallbladder) have been reported in GLP-1 receptor agonist trials and postmarketing and that in placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients-treated with Ozempic 0.5 mg and 1 mg, respectively
Ozempic Injury Lawsuit Claims
Ozempic stomach injury lawsuit cases potentially being investigated include claims involving individuals who, after taking Ozempic or similar diabetes and/or weight loss drugs, received medical treatment and/or were hospitalized for gastroparesis, gastrointestinal conditions or stomach issues or other issues, including:
- Gastroparesis
- Stomach paralysis
- Frozen stomach
- Delayed gastric emptying
- Intraoperative pulmonary aspiration
- Gastric stasis
- Gastroenteritis
- Ileus
- Intestinal obstruction
- Gastric blockage
- Bowel obstruction
- Severe and persistent vomiting
- Cyclical vomiting
- Severe and persistent diarrhea
- Severe and persistent nausea
- Gallbladder disease
- Gallbladder removal
- Esophageal injury requiring surgery
- GI injury requiring surgery
- Other gastrointestinal problems
- Deep vein thrombosis (DVT)
- Pulmonary embolism (PE)
- Sudden vision loss
- Non-Arteritic Anterior Ischemic Optic Neuropathy
- NAION
- Death
- Other Ozempic injury lawsuit cases
Time Is Limited To File An Ozempic Lawsuit
Deadlines known as statutes of limitation and statutes of repose may limit the time that individuals have to file a GLP-1 agonist or Ozempic lawsuit to try to recover compensation for injuries they claim to have suffered (e.g., stomach paralysis or other injury) after taking Ozempic and/or other similar diabetes or diet/weight loss drugs.
This means that if an Ozempic lawsuit claim is not filed before the applicable deadline or limitations period, the injured party may be barred from ever pursuing litigation or taking legal action regarding their Ozempic injury claim. That is why it is important to connect with an Ozempic injury lawyer or attorney as soon as possible.
If you or a loved one have suffered from gastroparesis (stomach paralysis), ileus, intraoperative pulmonary aspiration or other problems after taking Ozempic, Mounjaro, Wegovy, or Rybelsus, you may be entitled to recover compensation from an Ozempic lawsuit case or settlement claim. Contact a drug injury lawyer to request a free case review.
*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.
**The listing of a company (e.g., Novo Nordisk, Eli Lilly) or product (e.g., Ozempic, Mounjaro, Wegovy, or Rybelsus) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.
Fill out the form to request a free attorney review.